CONTEXT: Selective @entity750 reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressant, yet it is not known whether one SSRI is more effective than another. OBJECTIVE: To compare the effectiveness of 3 SSRIs ( @entity903 , @entity905 , and @entity3756 ) in depressed primary care @entity1 . DESIGN: Open-label, randomized, intention-to-treat trial, with @entity1 enrollment occurring in April-November 1999. SETTING: Thirty-seven clinics in 2 US primary care research networks. @entity1 : A total of 573 depressed adult @entity1 for whom their primary care physician thought that antidepressant therapy was warranted and who completed a baseline interview. INTERVENTIONS: @entity1 were randomly assigned to receive @entity903 (n = 189), @entity905 (n = 193), or @entity3756 (n = 191) for 9 months. Primary care physicians were allowed to switch @entity1 to a different SSRI or non-SSRI antidepressant if they did not adequately respond to or tolerate the initial SSRI. MAIN OUTCOME MEASURES: The primary outcome measure was change in the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) Mental Component Summary score (range, 0-100), compared across treatment groups at 1, 3, 6, and 9 months. Secondary outcomes included other @entity308 and psychological measures, multiple measures of social and work functioning, and other domains of health-related quality of life, such as physical functioning, concentration and memory, vitality, @entity158 , sleep, and sexual functioning. RESULTS: Follow-up interviews were successfully completed in 94% of @entity1 at 1 month, 87% at 3 months, 84% at 6 months, and 79% at 9 months. Responses to the 3 SSRIs were comparable on all measures and at all time points. The mean change in the SF-36 Mental Component Summary score at 9 months was + 15.8 in the @entity903 group, + 15.1 in the @entity905 group, and + 17.4 in the @entity3756 group. The drugs were also associated with similar incidences of adverse effects and discontinuation rates. CONCLUSIONS: The SSRI antidepressants @entity903 , @entity905 , and @entity3756 were similar in effectiveness for @entity308 as well as multiple domains of health-related quality of life over the entire 9 months of this trial.

Similar effectiveness of XXXX , @entity905 , and @entity3756 in primary care: a randomized trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive symptoms', 'depression'] @entity905 :: ('MESH:D005473', 'Chemical') :: ['fluoxetine'] @entity903 :: ('MESH:D017374', 'Chemical') :: ['paroxetine'] @entity3756 :: ('MESH:D020280', 'Chemical') :: ['sertraline'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin'] @entity158 :: ('MESH:D010146', 'Disease') :: ['bodily pain']
@entity903 :: (MESH:D017374,Chemical) :: ['paroxetine']
